If that is the case I would be worried that the US insurance companies will also be a hard sell.
I have been following AXP which also has a great product that really helps the patients, but they have really struggled to get surgeons to buy. I will keep an eye on AVH, but I think I want to see sales traction in the USA before buying in.
- Forums
- Commodities
- Biotech Analysts $4M pa
Biotech Analysts $4M pa, page-21
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)